KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.

Jian-Chun Duan, Jia Zhong, Bo-Yang Sun, Wen-Hua Zhao, Lin Wu, Kai-Lun Fei, Qian Chu, Qi-Sen Guo, Qi-Bin Song, Yan Yu, Da-Xing Zhu, Xin-Yan Liu, Jun Zhao, Zhi-Xiang Zhan, Shi Li, Lei Nie, Jie Lin, Xiao-Dong Peng, Dian-Sheng Zhong, Jin Zhou, Li-Hua Li, Yun-Fang Chen, Chen Hu, Tony Mok, Zhi-Jie Wang, Jie Wang

CA Cancer J Clin 76(2) e70071

PMID41818162
PMCIDPMC12981368
DOI10.3322/caac.70071
发表日期2026-03-12
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:森林图/亚组分析图;FIGURE 3:瀑布图。
摘要

摘要

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line therapy for advanced, EGFR-mutated nonsmall cell lung cancer (NSCLC). However, their benefit is limited in patients who have co-existing tumor suppressor gene (TSG) mutations, highlighting a need for intensified strategies to improve outcomes. ACROSS2 (ClinicalTrials.gov identifier NCT04500717) is the first prospective, multicenter, randomized phase 3 study to compare the third-generation EGFR-TKI aumolertinib in combination with carboplatin-pemetrexed versus aumolertinib monotherapy in patients who had NSCLC with EGFR mutations and concomitant TSG mutations. In total, 126 patients were enrolled and randomly assigned to either combination therapy (n = 62) or monotherapy (n = 64). The primary end point was median progression-free survival (PFS). At a median follow-up of 25.3 months, combination therapy significantly prolonged median PFS compared with monotherapy (19.78 vs 16.53 months; hazard ratio, 0.58; 95% confidence interval, 0.34-0.97). Landmark PFS rates at 12, 18, and 24 months were 78.7% versus 65.3%, 67.2% versus 40.8%, and 41.0% versus 29.9%, respectively. Subgroup analyses demonstrated a clear PFS benefit in patients who had co-existing tumor protein p53 (TP53) mutations. Grade 3 or greater adverse events occurred in 25.9% of patients who received combination therapy versus 17.2% of those who received monotherapy; no drug-related deaths were observed. Overall survival data were immature (data maturity, 4%). The ACROSS2 trial provides the first prospective evidence supporting a genotype-directed, chemotherapy-targeted intensification approach favoring aumolertinib plus carboplatin-pemetrexed for this molecularly defined population.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Overview of the included patients. AE indicates adverse event.
非 KM Figure
FIGURE 2Primary efficacy and subgroup analyses. (A) Kaplan–Meier plot of investigator‐assessed PFS in the intention‐to‐treat population; tick marks indicate censored observations. HRs and p values shown in the figure were derived from a stratified Cox model and a log‐rank test stratified by brain metastasis status and EGFR mutation subtype. (B) Forest plot of HRs for PFS across predefined stratification factors ( EGFR mutation subtype, CNS metastasis status) and exploratory subgroups. The HR for the total population was estimated using a stratified Cox model; HRs for all subgroup analyses were estimated using an unstratified Cox proportional hazards model. CI indicates confidence interval; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR , epidermal growth factor receptor; HRs, hazard ratios; mPFS, median progression‐free survival; TP53 , tumor protein p53.
非 KM Figure
FIGURE 3Waterfall plots of the best percentage change in the sum of greatest target lesion dimensions from baseline (full analysis set). (A) Aumolertinib plus carboplatin–pemetrexed. (B) Aumolertinib monotherapy. Plots include all patients who had at least one postbaseline overall assessment. The best response is defined as the overall assessment corresponding to the greatest percentage change from baseline. PD indicates progressive disease; PR, partial response; SD, stable disease.
非 KM Figure